Subretinal Hyperreflective Material in the Comparison of Age-Related XXXX Treatments Trials.

@entity1 @entity10691 @entity7 @entity941 @entity1020 @entity2246
PURPOSE: To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), @entity10691 ( @entity10691 ), and scar in the Comparison of Age-Related @entity1020 Treatments Trials (CATT). DESIGN: Prospective cohort study within a randomized clinical trial. @entity1 : The 1185 CATT @entity1 . METHODS: Masked readers graded scar and @entity10691 on fundus photography and @entity941 angiography and graded SHRM on time-domain and spectral-domain (SD) optical coherence tomography (OCT) throughout 104 weeks. Measurements of SHRM height and width in the fovea, within the center 1 mm(2), or outside the center 1mm(2) were obtained on SD OCT images at 56 (n  = 76) and 104 (n  = 66) weeks. MAIN OUTCOME MEASURES: Presence of SHRM, as well as location and size, and associations with VA, scar, and @entity10691 . RESULTS: Among CATT @entity1 , the percentage with SHRM at enrollment was 77%, decreasing to 68% at 4 weeks after treatment and to 54% at 104 weeks. At 104 weeks, scar was present more often in eyes with persistent SHRM than in eyes with SHRM that resolved (64% vs. 31%; P < 0.0001). Among eyes with detailed evaluation of SHRM at weeks 56 (n  = 76) and 104 (n  = 66), mean VA letter score was 73.5 ( @entity2246 [ @entity2246 ], 2.8), 73.1 ( @entity2246 , 3.4), 65.3 ( @entity2246 , 3.5), and 63.9 ( @entity2246 , 3.7) when SHRM was absent, present outside the central 1 mm(2), present within the central 1 mm(2) but not the foveal center, or present at the foveal center (P  = 0.02), respectively. When SHRM was present, the median maximum height under the fovea, within the central 1 mm(2) including the fovea and anywhere within the scan, was 86  m, 120  m, and 122  m, respectively. Visual acuity was decreased with greater SHRM height and width (P < 0.05). CONCLUSIONS: In eyes with neovascular @entity1020 ( @entity1020 ), SHRM is common and often persists after anti- @entity7 treatment. At 2 years, eyes with scar were more likely to have SHRM than other eyes. Greater SHRM dimensions were associated with worse VA. In eyes with @entity1020 , SHRM is an important morphologic biomarker.
